Literature DB >> 17099513

Vasoactivity of bovine polymerized hemoglobin (HBOC-201) in swine with traumatic hemorrhagic shock with and without brain injury.

Jennifer Rice1, Nora Philbin, Michael Handrigan, Carrie Hall, Gerald McGwin, Stephen Ahlers, L B Pearce, Francoise Arnaud, Richard McCarron, Daniel Freilich.   

Abstract

BACKGROUND: We previously reported that bovine polymerized hemoglobin (HBOC- 201) improved outcome in swine with hemorrhagic shock (HS) with and without traumatic brain injury (TBI). Herein, we add analyses of blood pressure (BP) responses, associated physiologic data, and HS fluid infusion guidelines.
METHODS: HBOC-201 versus standard fluid resuscitation was compared in four anesthetized invasively monitored swine models: moderate controlled HS, severe controlled HS, severe uncontrolled HS (liver injury), and severe uncontrolled HS/TBI (liver/parietal brain injuries). Pigs received fluid for hypotension and tachycardia, and were followed up to 6 (HS alone) or 72 hours (HS/TBI). The change in mean arterial pressure (DeltaMAP) response severity was stratified and analyzed based on infusion number and HS severity, using Student's t and Fisher's exact tests.
RESULTS: HBOC-201 vasoactivity resulted in higher MAP in all studies. Among HBOC-201 pigs, DeltaMAP responses were significant for the first two infusions and inversely related to HS severity. Among controls, DeltaMAP responses remained significant through the fourth infusion in controlled HS models, and through the first in severe uncontrolled HS/TBI; none were significant in severe uncontrolled HS. DeltaMAP was higher with HBOC-201 through the first infusion in moderate controlled HS, the fifth in severe uncontrolled HS, and the second in severe uncontrolled HS/TBI; there were no group differences in severe controlled HS. No severe MAP responses occurred. Higher DeltaMAP severity did not impact outcome. Hypotension satisfied fluid reinfusion criteria less consistently than tachycardia. Overall, HBOC-201 improved physiologic parameters and survival without causing hypoperfusion; in severe HS, perfusion improved.
CONCLUSIONS: In swine with HS +/- TBI, HBOC-201 had mild to moderate vasoactivity, resulting in significant DeltaMAP responses mainly after initial infusions, no severe/adverse responses, and improved outcome. Our data suggest that use of physiologic parameters (e.g., tachycardia), in addition to hypotension to guide fluid reinfusion during HS resuscitation with HBOC-201, will minimize hypoperfusion risk and maximize potential benefit.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17099513     DOI: 10.1097/01.ta.0000236640.62893.fa

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  5 in total

1.  Simulation of NO and O2 transport facilitated by polymerized hemoglobin solutions in an arteriole that takes into account wall shear stress-induced NO production.

Authors:  Yipin Zhou; Pedro Cabrales; Andre F Palmer
Journal:  Biophys Chem       Date:  2012-01-09       Impact factor: 2.352

2.  Vital organ tissue oxygenation after serial normovolemic exchange transfusion with HBOC-201 in anesthetized swine.

Authors:  William W Muir; Govindasamy Ilangovan; Jay L Zweier; Paula F Moon-Massat; Virginia T Rentko
Journal:  Shock       Date:  2011-06       Impact factor: 3.454

3.  Fluid resuscitation of uncontrolled hemorrhage using a hemoglobin-based oxygen carrier: effect of traumatic brain injury.

Authors:  Nathan J White; Xu Wang; Nicole Bradbury; Paula F Moon-Massat; Daniel Freilich; Charles Auker; Richard McCarron; Anke Scultetus; Susan A Stern
Journal:  Shock       Date:  2013-02       Impact factor: 3.454

Review 4.  Bench-to-bedside review: latest results in hemorrhagic shock.

Authors:  Martin K Angele; Christian P Schneider; Irshad H Chaudry
Journal:  Crit Care       Date:  2008-07-10       Impact factor: 9.097

Review 5.  New Applications of HBOC-201: A 25-Year Review of the Literature.

Authors:  Min Cao; Yong Zhao; Hongli He; Ruiming Yue; Lingai Pan; Huan Hu; Yingjie Ren; Qin Qin; Xueliang Yi; Tao Yin; Lina Ma; Dingding Zhang; Xiaobo Huang
Journal:  Front Med (Lausanne)       Date:  2021-12-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.